0001267565 false 0001267565 2025-05-08 2025-05-08

​

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

​

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): May 8, 2025

​

COLLEGIUM PHARMACEUTICAL, INC.

​

(Exact name of registrant as specified in its charter)

​

​ | ​ | ​
Virginia | 001-37372 | 03-0416362
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
​ | ​ | ​
​ | 100 Technology Center Drive | ​
​ | Suite 300 | ​
​ | Stoughton, MA 02072 | ​
​ | (Address of principal executive offices) (Zip Code) | ​

​

Registrant’s telephone number, including area code: (781) 713-3699

​

(Former name or former address, if changed since last report.)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​ | ​ | ​
Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | COLL | The NASDAQ Global Select Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

​

Item 2.02 Results of Operations and Financial Condition.

​

On May 8, 2025, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period ended March 31, 2025. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 2.02 of this Current Report on Form 8-K.

​

Item 7.01 Regulation FD Disclosure.

​

On May 8, 2025, Collegium Pharmaceutical, Inc. released an earnings presentation. The presentation is attached hereto as Exhibit 99.2 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K.

​

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

​

​ | ​ | ​
Exhibit |  | ​
No. | ​ | Description
99.1 | ​ | Press Release, dated May 8, 2025
99.2 | ​ | Earnings Presentation, dated May 8, 2025
104 | ​ | Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​ | ​ | ​
​ | Collegium Pharmaceutical, Inc.
​ | ​ | ​
​ | By: | /s/ Colleen Tupper
​ | ​ | Colleen Tupper
​ | ​ | Executive Vice President and Chief Financial Officer

​

Dated: May 8, 2025

​

​